|
|
News Breaks | | | | January 17, 2013 | | 19:36 EDT |  | PATH | NuPathe gaps up after Zecuity receives FDA approval
In the extended session Thursday, the shares were trading up at $3.93 after Zecuity was approved by the FDA. At current levels, next resistance is at $4.15, and then at $4.43. Support is at $3.88. | |
|
News For PATH From The Last 14 Days Check below for free stories on PATH the last two weeks. |
|
|
| May 14, 2013 | | 07:38 EDT |  | PATH | NuPathe reports Q1 EPS (68c) with items, consensus (17c)
 Subscribe for More Information | | | May 13, 2013 | | 15:27 EDT | | PATH | Notable companies reporting after market close
Notable companies reporting before tomorrow's open, with earnings consensus, include AutoNavi Holdings (AMAP), consensus 19c; Hi-Crush Partners (HCLP), consensus 50c; Global Sources (GSOL), one estimate 17c; General Finance (GFN), one estimate 11c; NuPathe (PATH), consensus (17c). | | | 08:22 EDT |  | PATH | NuPathe announces allowance of U.S. patent application for NP201
Subscribe for More Information | |
|
|
|
|
|
|
